COVID-19 patients on VV-ECMO support suffer from strikingly high intracerebral bleeding rates. In this recent study, collaborating with colleagues from the BIDMC (Harvard, Boston), we could demonstrate that adjustments to less aggressive anticoagulation targets lead to a significant reduction in intracerebral bleeding complications in these patients. Our findings have high practical value and importance.
Find the article under https://icm-experimental.springeropen.com/articles/10.1186/s40635-023-00525-3 or read it on our website.
Comentários